Skip to content
Corporate Social Responsibility
Fact Sheet Management Team Board of Directors Corporate Social Responsibility Ethics Advisory Board

ESG Hub

Environmental, social, and governance hub

Environmental, social, and governance hub

We aim for transparent disclosure of our environmental, social, and governance (ESG) practices and progress, underscored by a commitment to continuous improvement

Our CSR Vision - deepening our impact on human health by serving as a champion for patients, our communities, our people, and our planet.
America's Most Just Companies
FTSE4Good logo
ECOVADIS logo
Dow Jones Sustainability Indicies
Sustainalytics
CDP

Progress towards our 2030* goals

net zero

Net Zero
carbon emissions by 2050 in operations and value chain
2022 Progress: committed

ghg emissions

46%
reduction in absolute Scope 1, 2 & 3 GHG emissions
2022 Progress: Scope 1 & 2: 100%2
Scope 3: ↑51%

reduction in packaging

75%
reduction in packaging
2022 Progress: 30%

lives covered by genomic testing

2 billion
lives covered by genomic testing globally (2026)
Progress: 1.2 billion

cost per genome

$100
cost per genome
Progress: $2003

STEM learners

5 million
STEM learners reached
Progress: 1.2 million

gender representation

Increase
gender representation in leadership1
2022 Progress: 41%

representation

Increase
representation of Black, Native, Pacific Islander, Hispanic or Latino, and two or more communities in our US workforce and leadership

diverse suppliers

20%
spend allocated to diverse suppliers
2022 Progress: 18%

Download 2030 Targets
  • * 2019 baseline
  • 1. Leadership = Manager, equivalent, and above
  • 2. *Scope 1 reductions include our beyond SBTi mitigation, applying Green E certified Carbon Offsets for our natural gas Scope 1. Scope 2 reductions include the combination of on-site solar, purchased renewable electricity, and renewable electricity credits.
  • 3. ~$200, based on US list price, assuming 120 Gb/genome; compared to NovaSeqTM 6000.
CSR cover
Learn about the progress we have made to shape a more sustainable and equitable future for all.
English Simplified Chinese French Spanish
 Download ESG Appendix
Download Executive Summary
CSR Report Archive
CSR cover
English Simplified Chinese
CSR cover
English Simplified Chinese
CSR cover

2019

ESG Framework Indexes

Global Reporting Initiative

Sustainable Accounting Standards Board (SASB)

Task Force on Climate-Related Financial Disclosure

United National Global Compact

United Nations Sustainable Development Goals

ESG Data

Appendix

Assurance Statements

2022 CDP Response

2020 TCFD & Climate Scenario Analysis

SEC Filings

Proxy Filings

10-K Filing

DEI Data

2021 EEO-1 Report

2020 EEO-1 Report

L’égalité professionnelle Femmes/Hommes 2022

L’égalité professionnelle Femmes/Hommes 2021

L’égalité professionnelle Femmes/Hommes 2020

L’égalité professionnelle Femmes/Hommes 2019

France Gender Equality Index 2022

France Gender Equality Index 2021

France Gender Equality Index 2020

UK Gender Pay Gap Report 2022

UK Gender Pay Gap Report 2021

UK Gender Pay Gap Report 2020

UK Gender Pay Gap Report 2019

UK Gender Pay Gap Report 2018

UK Gender Pay Gap Report 2017

Our 2030 Targets and Policies

Corporate policies here

Environmental

  • Net Zero in operations and value chain by 2050
  • Carbon neutral in direct operations (Scopes 1 and 2) by 2023 beyond SBTi verified targets
  • $20 million philanthropic support for Sustainability Initiatives
  • 100% renewable electricity by 2030
  • 46% emission reduction Scope 1,2,3 by 2030
  • 10% reduction water intensity by 2030
  • 90% landfill waste diversion by 2030
  • Green design principles in new construction with LEED elements or equivalent
  • 75% reduction in packaging
  • 90% of secondary and tertiary packaging will be recyclable, reusable, or compostable
  • Reduce energy intensity of sequencers
  • Reduce petroleum-based plastic use
  • Replace chemicals of concern with green alternatives wherever possible
  • Increase product take back and circular economy opportunities
  • 100% of strategic suppliers commit to minimizing their environmental footprint

Social

  • $100 genome
  • 2 billion covered lives by 2026
  • Reach 25,000 learners annually with education across all clinical segments
  • Expand on the independent medical educational partnerships with professional societies and the medical community, with knowledge and competence increases demonstrated in >95% of programs
  • Reach over 200 organizations through Illumina for Startups
  • 50,000 patients supported through iHope programming
  • $60 million PGI commitment implemented by 2027
  • 50% employee participation (giving + volunteering)
  • 100,000 volunteer hours donated
  • Achieve 90% positive survey rate on employee's response to Illumina Cares programming and connection to our mission
  • 5 million STEM learners reached through direct programming and nonprofit donations
  • $20 million philanthropic support for Sustainability Initiatives
  • Increase prevention-based safety reporting and decrease injury and illness rates
  • Increase gender representation in leadership
  • Increase Black, Native, Pacific Islander, Hispanic or Latino, and two or more communities in leadership (US)
  • Increase representation of Black, Native, Pacific Islander, Hispanic or Latino, and two or more communities in workforce (US)
  • Maintain zero net pay gap
  • Increase minority representation in executive leadership (US)
  • Increase gender representation of women in global leadership
  • Improve representation of Veterans in the workforce
  • Improve representation of disability workforce
  • Create a working environment where neuro-diversity and people with disabilities can thrive
  • Acquire and develop diverse talent to drive inclusion and representation 
  • Establish a culture where minorities can thrive and progress with the company as we build a strong pipeline 
  • Create an innovative organization where young and mature talent feel involved, respected, connected, and inspired to contribute new ideas 
  • Build our global workforce to represent the communities where we operate and the world we are working to serve

Governance

  • 20% of yearly spend with diverse suppliers (US)
  • Demonstrate responsible data stewardship with strong privacy and cybersecurity practices
  • Position Illumina as the most trusted company in genomic privacy and ethics
  • Continue working to ensure human rights are respected in our workplace, our supply chain, and the marketplace
  • Maintain a corporate governance framework to promote ethics and integrity in all we do

Recognition

2022 Fast Company Most Innovative Companies
2023 America Most Just Companies CNBC
AmCham CARES Singapore 2022 High Distinction
2023 Best Places to Work presented by BioSpace
2022 3BL ME DIA 100 Best Corporate Citizens
2023 ESG Industry Top Rated - Morningstar Sustainalytics
North American Customer Centricity Awards - Winner 2022
2023 The Straits Times Singapore's Best Employers
2022 Newsweek - America's Most Responsible Companies
2022 Forbes - World's Top Female Friendly Companies
2022 Best Places to Work LGBTQ+ Equality
Forbes 2022 - World's Best Employers
Bloomberg Gender-Equality Index - 2023 Member
DEI 2022 - Best Place to work for Disability Inclusion
2023 Newsweek - America's Greatest Workplaces for Diversity
2022 Military Times - Best for Vets Employers
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2023 Illumina, Inc. All rights reserved.